Galectin Therapeutics (GALT) Stock Price, News & Analysis

Company Overview

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Key Stats

• Today's Range: $1.21 to $1.29
• 50-Day Range: $0.84 to $2.96
• 52-Week Range: $0.73 to $4.27
• Volume: 229,512 shs
• Average Volume: 910,344 shs
• Market Capitalization: $77.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Hold

Galectin Therapeutics Stock Analysis - MarketRank™

Galectin Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 692nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Galectin Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Galectin Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Galectin Therapeutics are expected to decrease in the coming year, from ($0.73) to ($0.92) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Galectin Therapeutics is -1.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Galectin Therapeutics is -1.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.54% of the float of Galectin Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Galectin Therapeutics has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Galectin Therapeutics has recently decreased by 2.78%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Galectin Therapeutics does not currently pay a dividend.

Dividend Growth

Galectin Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

18.54% of the float of Galectin Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Galectin Therapeutics has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Galectin Therapeutics has recently decreased by 2.78%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.67

News Sentiment

Galectin Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Galectin Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 5 people have searched for GALT on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

7 people have added Galectin Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Galectin Therapeutics insiders have sold 471.92% more of their company's stock than they have bought. Specifically, they have bought $17,040.00 in company stock and sold $97,456.00 in company stock.

Percentage Held by Insiders

50.10% of the stock of Galectin Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 11.68% of the stock of Galectin Therapeutics is held by institutions.

GALT Stock Analysis - Frequently Asked Questions

How have GALT shares performed this year?

Galectin Therapeutics' stock was trading at $1.29 at the beginning of 2025. Since then, GALT shares have decreased by 3.9% and is now trading at $1.24.
View the best growth stocks for 2025 here.

How were Galectin Therapeutics' earnings last quarter?

Galectin Therapeutics Inc. (NASDAQ:GALT) announced its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.04.

Who are Galectin Therapeutics' major shareholders?

Galectin Therapeutics' top institutional shareholders include Traynor Capital Management Inc. (0.09%), Wealth Enhancement Advisory Services LLC (0.08%) and FNY Investment Advisers LLC. Insiders that own company stock include James C Czirr, Joel Lewis, Kary Eldred, Richard A Jr Zordani, Kevin D Freeman, Khurram Jamil, Harold H Shlevin, Jack W Callicutt, Fund LP 10X and Elissa J Schwartz.
View institutional ownership trends.

How do I buy shares of Galectin Therapeutics?

Shares of GALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Galectin Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Galectin Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 8/13/2024
• Today: 1/21/2025
• Next Earnings (Estimated): 4/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GALT
• CUSIP: N/A
• CIK: 1133416
• Web: www.galectintherapeutics.com
• Phone: (678) 620-3186
• Fax: 770-864-1327
• Employees: 9
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.00
• High Stock Price Target: $11.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +787.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-41,070,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -163.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.13
• Quick Ratio: 1.13

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.01) per share
• Price / Book: -1.23

Miscellaneous

• Outstanding Shares: 62,760,000
• Free Float: 31,318,000
• Market Cap: $77.82 million
• Optionable: Optionable
• Beta: 0.83